Cabaletta Bio, Inc. — Form 10-Q Summary
Reporting period: Three months ended March 31, 2020; filed May 12, 2020. Cabaletta Bio is a clinical-stage biotechnology company developing engineered CAAR T-cell therapies for B-cell-mediated autoimmune diseases. The company had no approved products and no product revenue.
Business Context and Development Status
- Lead candidate DSG3-CAART targets mucosal pemphigus vulgaris. Its IND was cleared in September 2019, and the company planned to initiate the Phase 1 DesCAARTes trial in 2020.
- DSG3-CAART received FDA orphan drug designation in January 2020 and fast track designation in May 2020 for improving mucosal blister healing in patients with mucosal pemphigus vulgaris.
- Other programs, including MuSK-CAART, DSG3/1-CAART and FVIII-CAART, remained in discovery or preclinical development.
- The company relied substantially on the University of Pennsylvania and affiliated entities for research, development, manufacturing and clinical support.
Financial Results and Key Metrics
| Metric | Q1 2020 | Q1 2019 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $4.620 million | $2.761 million | +$1.859 million |
| General and administrative expense | $3.275 million | $1.229 million | +$2.046 million |
| Total operating expenses | $7.895 million | $3.990 million | +$3.905 million |
| Loss from operations | $(7.895) million | $(3.990) million | $(3.905) million |
| Interest income | $0.410 million | $0.458 million | $(0.048) million |
| Net loss | $(7.485) million | $(3.532) million | $(3.953) million |
| Net loss attributable to common stockholders | $(7.485) million | $(8.858) million | Improved by $1.373 million |
| Basic and diluted loss per share | $(0.33) | $(6.05) | Improved |
Gross margin, operating margin and net margin are not meaningful because the company generated no revenue. Stock-based compensation was $0.873 million in Q1 2020 versus $0.496 million in Q1 2019.
Cash Flow, Liquidity and Capitalization
- Cash and cash equivalents were $131.003 million at March 31, 2020, down from $136.204 million at December 31, 2019.
- Operating cash use was $4.931 million, compared with $2.265 million in the prior-year quarter.
- Investing cash use was $0.226 million, primarily for property and equipment.
- Financing cash use was $0.044 million, principally for common-stock issuance costs. Q1 2019 financing cash flow included $49.663 million of preferred-stock proceeds.
- Total current liabilities were $3.256 million at March 31, 2020. The filing does not disclose outstanding debt or a credit facility; management stated that it had no credit facility or committed sources of capital.
- Accumulated deficit was $40.444 million, compared with $32.959 million at December 31, 2019.
- There were 24,034,022 common shares outstanding at March 31, 2020 and May 8, 2020. No preferred stock was outstanding following its conversion in connection with the 2019 IPO.
- Management stated that cash at March 31, 2020 was expected to fund operations for at least 12 months following the financial statement date. The MD&A separately stated that, under its current operating plan, cash was expected to fund operations through at least the third quarter of 2022; this estimate depends on assumptions that may prove incorrect.
Material Changes Versus the Prior Comparable Period
- Total operating expenses increased 98%, driven by higher research activity, employee additions, clinical-trial start-up costs, manufacturing activity and public-company expenses.
- Research and development expense increased 67%. Key increases included personnel costs of approximately $1.1 million, development and sponsored research costs of approximately $0.4 million, initial clinical-trial costs of approximately $0.3 million and manufacturing start-up costs of approximately $0.1 million.
- General and administrative expense increased 166%, including higher personnel and stock-based compensation, insurance, legal, audit, accounting, recruiting and public-relations costs.
- Net loss increased from $3.532 million to $7.485 million. The prior-year net loss attributable to common stockholders included a $5.326 million deemed dividend related to a preferred-stock exchange; no such charge occurred in 2020.
- Operating cash burn more than doubled year over year, while the company had substantial cash following its 2019 IPO.
Guidance, Outlook, Risks and Unusual Items
- The company expected research and development and general and administrative expenses to increase substantially as clinical development, manufacturing activities and public-company infrastructure expanded.
- The company expected to remain unprofitable and generate operating losses for the foreseeable future, with additional financing likely required. Potential sources included equity, debt, government funding, strategic alliances and licensing arrangements.
- COVID-19 had not significantly affected Q1 2020 financial results, but management could not predict its full effect on clinical-trial timing, patient enrollment, manufacturing, suppliers, operations or access to capital. Employees largely shifted to remote work in March 2020.
- COVID-19-related risks included delays in clinical-site activation and monitoring, patient recruitment, supply shipments, manufacturing and regulatory interactions, as well as increased volatility in capital markets.
- Material commitments included an office lease with approximately $0.624 million of future minimum payments, sponsored research commitments through April 2021, up to $2.0 million of potential manufacturing-related commitments over the following nine months, and possible milestone payments to Penn that could approach $20 million if multiple products are successfully developed and launched. Penn is also eligible for royalties and sublicense income.
- The company’s principal risks included clinical and regulatory failure, serious adverse events associated with CAAR T-cell therapies, manufacturing and supply-chain constraints, reliance on Penn and other third parties, intellectual-property challenges, additional financing needs and shareholder dilution.
- The company reported no material litigation, no off-balance-sheet arrangements and no material changes in contractual obligations from December 31, 2019. Disclosure controls and procedures were assessed as effective at a reasonable assurance level.
Important Facts for Investors to Verify
- Whether the DesCAARTes Phase 1 trial began on schedule and whether COVID-19 affected enrollment, dosing or timelines.
- Clinical safety, tolerability, dose-escalation and efficacy data for DSG3-CAART, including risks of cytokine release syndrome, neurotoxicity and off-target effects.
- Actual cash burn and runway relative to management’s stated funding horizon through at least the third quarter of 2022.
- Timing and terms of any future equity or debt financing, including potential dilution and whether the company can fund later-stage clinical development.
- Progress in transferring manufacturing from Penn to contract manufacturers or internal facilities, including lentiviral-vector supply and process comparability.
- Compliance with Penn license, sponsored research and milestone obligations, and the potential future royalty and milestone burden.
- Whether orphan drug and fast track designations produce meaningful regulatory or development benefits; neither designation assures approval.